Cargando…

Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities

High-dose methotrexate is a cornerstone agent in the chemotherapeutic treatment of patients with osteosarcoma. However, patients often develop methotrexate-induced toxicities. We aim to identify determinants of methotrexate-induced toxicities in osteosarcoma patients by investigating the relation be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurkmans, Evelien G. E., Klumpers, Marije J., Vermeulen, Sita H., Hagleitner, Melanie M., Flucke, Uta, Schreuder, H. W. Bart, Gelderblom, Hans, Bras, Johannes, Guchelaar, Henk-Jan, Coenen, Marieke J. H., te Loo, D. Maroeska W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435008/ https://www.ncbi.nlm.nih.gov/pubmed/32903464 http://dx.doi.org/10.3389/fphar.2020.01241

Ejemplares similares

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma
por: Boccia, Stefania, et al.
Publicado: (2015)

Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
por: Hurkmans, Evelien G. E., et al.
Publicado: (2023)

Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury
por: Klumpers, Marije J., et al.
Publicado: (2022)

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review
por: Hurkmans, Evelien G. E., et al.
Publicado: (2022)

Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia
por: Lopes, Bruno Almeida, et al.
Publicado: (2015)

Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts
por: Hagleitner, Melanie M., et al.
Publicado: (2014)

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
por: Sanchez-Spitman, A. B., et al.
Publicado: (2018)

Contribution of common and rare genetic variants in CEP72 on vincristine‐induced peripheral neuropathy in brain tumour patients
por: Klumpers, Marije J., et al.
Publicado: (2022)

CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study
por: Opdam, F. L., et al.
Publicado: (2015)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
por: Fernández-Santander, Ana, et al.
Publicado: (2013)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin
por: Hurkmans, Evelien G. E., et al.
Publicado: (2022)

Action of Halowax 1051 on Enzymes of Phase I (CYP1A1) and Phase II (SULT1A and COMT) Metabolism in the Pig Ovary
por: Barć, Justyna, et al.
Publicado: (2013)

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
por: van Eerden, Ruben A. G., et al.
Publicado: (2023)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma
por: Hagleitner, Melanie M., et al.
Publicado: (2012)

Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques
por: UNO, Yasuhiro, et al.
Publicado: (2014)

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19
por: Koopmans, Anne B., et al.
Publicado: (2021)

Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk
por: Bethke, Lara, et al.
Publicado: (2007)

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
por: Schmidt, R, et al.
Publicado: (2004)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers
por: Al-saraireh, Yousef M., et al.
Publicado: (2021)

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1
por: Edavana, Vineetha Koroth, et al.
Publicado: (2011)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
por: Denisenko, Natalia P, et al.
Publicado: (2018)

MD Investigation on the Interaction between Carbamazepine and Two CYP Isoforms, CYP3A4 and CYP3A5
por: Liu, Shuhui, et al.
Publicado: (2023)

CYP3A4 and CYP3A5 genotyping by Pyrosequencing
por: Garsa, Adam A, et al.
Publicado: (2005)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice
por: Kapelyukh, Y., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3onhl4bmbjkd7ddi5g6p8gbfcg